Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?
• By The Pink Sheet Daily
Agency's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will be asked to weigh pre-approval data requirements and discuss innovative approaches to boosting drug development for rare diseases at its March 2 meeting.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
